Related Experiment Videos
Animal models of endotoxic shock
1Cellular and Molecular Pharmacology Section, Institute of Neuroscience, Milan, Italy.
Methods in Molecular Medicine
|April 6, 2004
Summary
Lipopolysaccharide (LPS) drives Gram-negative bacterial shock responses, primarily via tumor necrosis factor alpha (TNFα). Animal models are crucial for studying TNFα
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Endotoxin/lipopolysaccharide (LPS) is a key mediator in Gram-negative bacterial infections, triggering significant immune responses and shock.
- Tumor necrosis factor alpha (TNFα) plays a central role in mediating the toxic effects of LPS during endotoxic and septic shock.
- Understanding LPS-induced shock requires robust experimental models to investigate therapeutic interventions.
Purpose of the Study:
- To review widely used animal models for studying endotoxic/septic shock.
- To examine the role of TNFα in LPS-induced shock.
- To identify potential anti-TNFα molecules for therapeutic development.
Main Methods:
- Description of high-dose LPS models in mice.
- Description of low-dose LPS with D-galactosamine sensitization models.
- Introduction to the polymicrobial cecal ligation and puncture (CLP) model for complex shock studies.
Main Results:
- LPS administration, in various models, leads to measurable endpoints including survival rates, organ toxicity, and cytokine regulation, particularly TNFα levels.
- These models allow for the assessment of TNFα's involvement and the efficacy of potential anti-TNFα therapies.
- The CLP model highlights the synergistic interactions of multiple mediators in a more complex septic shock scenario.
Conclusions:
- Established animal models are essential for dissecting the mechanisms of endotoxic/septic shock and for evaluating anti-TNFα strategies.
- Different models offer varying levels of complexity, from direct LPS challenge to polymicrobial sepsis, each providing unique insights.
- Further research using these models can lead to the development of novel treatments for life-threatening Gram-negative bacterial infections.